345 related articles for article (PubMed ID: 23768070)
21. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
22. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
[TBL] [Abstract][Full Text] [Related]
23. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms.
Ferrari A; Scandura J; Masciulli A; Krichevsky S; Gavazzi A; Barbui T
Eur J Haematol; 2021 Feb; 106(2):250-259. PubMed ID: 33135220
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
26. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
27. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; McMahon B; Mohan SR; Oh S; Padron E; Papadantonakis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2017 Oct; 15(10):1193-1207. PubMed ID: 28982745
[TBL] [Abstract][Full Text] [Related]
28. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
Bankar A; Chan WC; Liu N; Cheung M; Alibhai S; Gupta V
Blood Adv; 2023 Sep; 7(17):5014-5026. PubMed ID: 37184988
[TBL] [Abstract][Full Text] [Related]
30. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
31. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
32. Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs.
Fowlkes S; Murray C; Fulford A; De Gelder T; Siddiq N
Can Oncol Nurs J; 2018; 28(4):276-281. PubMed ID: 31148831
[TBL] [Abstract][Full Text] [Related]
33. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
[TBL] [Abstract][Full Text] [Related]
34. Serum chitotriosidase: a circulating biomarker in polycythemia vera.
Krecak I; Gveric-Krecak V; Roncevic P; Basic-Kinda S; Gulin J; Lapic I; Fumic K; Ilic I; Horvat I; Zadro R; Holik H; Coha B; Peran N; Aurer I; Durakovic N
Hematology; 2018 Dec; 23(10):793-802. PubMed ID: 29993340
[TBL] [Abstract][Full Text] [Related]
35. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
[TBL] [Abstract][Full Text] [Related]
36. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
Radia D; Geyer HL
Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
[TBL] [Abstract][Full Text] [Related]
37. Myeloproliferative syndromes and the associated risk of coronary artery disease.
Ganti AK; Potti A; Koka VK; Pervez H; Mehdi SA
Thromb Res; 2003 May; 110(2-3):83-6. PubMed ID: 12893021
[TBL] [Abstract][Full Text] [Related]
38. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
[TBL] [Abstract][Full Text] [Related]
39. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
Int J Cancer; 2014 Apr; 134(7):1741-50. PubMed ID: 24114627
[TBL] [Abstract][Full Text] [Related]
40. [Research progress of myeloproliferative neoplasms].
He HJ; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):278-84. PubMed ID: 25687088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]